Cargando…
A blood-based signature of cerebrospinal fluid Aβ(1–42) status
It is increasingly recognized that Alzheimer’s disease (AD) exists before dementia is present and that shifts in amyloid beta occur long before clinical symptoms can be detected. Early detection of these molecular changes is a key aspect for the success of interventions aimed at slowing down rates o...
Autores principales: | Goudey, Benjamin, Fung, Bowen J., Schieber, Christine, Faux, Noel G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6409361/ https://www.ncbi.nlm.nih.gov/pubmed/30853713 http://dx.doi.org/10.1038/s41598-018-37149-7 |
Ejemplares similares
-
Distributions of Aβ42 and Aβ42/40 in the Cerebrospinal Fluid in View of the Probability Theory
por: Lewczuk, Piotr, et al.
Publicado: (2021) -
Prediction of P-tau/Aβ42 in the cerebrospinal fluid with blood microRNAs in Alzheimer’s disease
por: Jia, Longfei, et al.
Publicado: (2021) -
Cerebrospinal Fluid Aβ(42/40) Corresponds Better than Aβ(42) to Amyloid PET in Alzheimer’s Disease
por: Lewczuk, Piotr, et al.
Publicado: (2016) -
Cerebrospinal fluid ratios with Aβ(42) predict preclinical brain β-amyloid accumulation
por: Racine, Annie M., et al.
Publicado: (2015) -
Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE
por: Ayton, Scott, et al.
Publicado: (2015)